Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 15 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Lazaridis, Georgios  [Clear All Filters]
Journal Article
Patsatsi, A., Kyriakou A., Karavasilis V., Tsatsou F., Lazaridis G., Kalabalikis D., et al. (2014).  Acquired ichthyosis triggered by an osseous hemangiopericytoma: a case report and review of the literature.. Case Rep Dermatol. 6(1), 10-5.
Psyrri, A., Kalogeras K. T., Wirtz R. M., Kouvatseas G., Karayannopoulou G., Goussia A., et al. (2017).  Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.. J Transl Med. 15(1), 30.
Stavridi, F., Kalogeras K. T., Pliarchopoulou K., Wirtz R. M., Alexopoulou Z., Zagouri F., et al. (2016).  Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.. PLoS One. 11(10), e0164013.
Mountzios, G., Kotoula V., Kolliou G-A., Papadopoulou K., Lazaridis G., Christodoulou C., et al. (2019).  Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab.. ESMO Open. 4(2), e000441.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Koutras, A., Lazaridis G., Koliou G-A., Kouvatseas G., Christodoulou C., Pectasides D., et al. (2018).  Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.. PLoS One. 13(12), e0207707.
Kotoula, V., Fostira F., Papadopoulou K., Apostolou P., Tsolaki E., Lazaridis G., et al. (2017).  The fate of BRCA1-related germline mutations in triple-negative breast tumors.. Am J Cancer Res. 7(1), 98-114.
Papadopoulou, K., Murray S., Manousou K., Tikas I., Dervenis C., Sgouros J., et al. (2018).  Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.. Am J Cancer Res. 8(1), 2-15.
Pentheroudakis, G., Raptou G., Kotoula V., Wirtz R. M., Vrettou E., Karavasilis V., et al. (2015).  Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.. PLoS One. 10(5), e0124612.
Lazaridis, G., Kotoula V., Vrettou E., Kostopoulos I., Manousou K., Papadopoulou K., et al. (2019).  Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer.. Cancer Genomics Proteomics. 16(3), 195-206.
Kotoula, V., Lakis S., Tikas I., Giannoulatou E., Lazaridis G., Papadopoulou K., et al. (2019).  Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.. Gynecol Oncol. 152(2), 375-386.
Economopoulou, P., Kotoula V., Koliou G-A., Papadopoulou K., Christodoulou C., Pentheroudakis G., et al. (2019).  Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.. Transl Oncol. 12(5), 739-748.
Strati, T-M., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Lazaridis G., et al. (2017).  Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.. Anticancer Res. 37(5), 2323-2334.
Zagouri, F., Kotoula V., Kouvatseas G., Sotiropoulou M., Koletsa T., Gavressea T., et al. (2017).  Protein expression patterns of cell cycle regulators in operable breast cancer.. PLoS One. 12(8), e0180489.
Kotoula, V., Tsakiri K., Koliou G-A., Lazaridis G., Papadopoulou K., Giannoulatou E., et al. (2019).  Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.. Clin Breast Cancer. 19(2), 113-125.e4.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.